Novo Nordisk Mexico and the Salvador Zubirán Institute signed a major agreement to develop clinical studies in cardiometabolic and rare diseases, aiming to boost Mexico's scientific presence. In a move to elevate Mexico’s position on the global scientific stage, Danish pharmaceut…
